GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: DS-6000 | DS-6000A | R-DXd
Compound class:
Antibody
Comment: Raludotatug deruxtecan (R-DXd; DS-6000a) is an anti-CDH6 monoclonal conjugated to the chemotherapy agent deruxtecan (DXd; a derivative of the topoisomerase I inhibitor exatecan) [1-2]. The antitumour effect of raludotatug deruxtecan is due to intracellular release of the toxic payload; the naked antibody has no anti-tumour activity.
|
| No information available. |
Summary of Clinical Use  |
| Raludotatug deruxtecan (R-DXd; DS-6000a) was progressed as a clinical candidate for the treatment of advanced solid tumours. In September 2025 the FDA issued Breakthrough Therapy Designation for raludotatug deruxtecan to treat CDH6-positive gynaecologic cancers (post-bevacizumab treatment) [3]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06660654 | A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) | Phase 2 Interventional | Daiichi Sankyo | ||
| NCT06864169 | A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | Phase 2 Interventional | Merck Sharp & Dohme LLC | ||
| NCT06780098 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | Phase 2 Interventional | Merck Sharp & Dohme LLC | ||
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Phase 2/Phase 3 Interventional | Daiichi Sankyo | ||
| NCT04707248 | A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | Phase 1 Interventional | Daiichi Sankyo | 2 | |
